Rate My Professor James Fang

James C. Fang, M.D., serves as Chief of Cardiovascular Medicine at the University of Utah School of Medicine, Director of the Cardiovascular Service Line at University of Utah Health Care, and holds the John and June B. Hartman Presidential Endowed Chair in addition to the Professor of Medicine position. He earned a B.A. with a major in Mathematics and minor in Chemistry from Duke University in 1984, followed by an M.D. from Duke University School of Medicine in 1988. Dr. Fang completed his internship, residency, and chief residency in internal medicine at Johns Hopkins Hospital by 1993. He then pursued cardiovascular fellowship training in 1996 and heart failure/transplant fellowship in 1997 at Brigham and Women’s Hospital/Harvard Medical School, along with postgraduate studies in the Program in Clinical Effectiveness at Harvard School of Public Health.

Dr. Fang's academic career began with a faculty appointment at Brigham and Women’s Hospital/Harvard Medical School from 1997 to 2006, rising to Associate Professor of Medicine. In 2006, he joined University Hospitals/Case Western Reserve University School of Medicine in Cleveland as Clinical Chief of Cardiovascular Medicine and Associate Chief for Clinical Affairs, Medical Director of the Heart Failure, Transplant, and Circulatory Assist Program, and Chief Medical Officer for the Harrington Heart and Vascular Institute, holding the Spitz Master Clinician Chair. He moved to the University of Utah in 2013 to lead the Division of Cardiovascular Medicine. An accomplished researcher, Dr. Fang has authored over 175 original articles, editorials, and book chapters. Key publications include 'Hemodynamics for the Heart Failure Clinician: A State-of-the-Art Review' (2022), 'Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel' (2020), 'World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult' (2012), and 'Physical Activity and Prognosis in the TOPCAT Trial' (2017). His research focuses on heart failure with preserved ejection fraction, advanced heart failure, coronary artery vasculopathy of the transplanted heart, and cardiorenal syndrome. Dr. Fang received the Laennec Master Clinician Award from the American Heart Association in 2014 and served as the 18th President of the Heart Failure Society of America in 2023. He has contributed to position statements for the Heart Failure Society of America and the International Society for Heart and Lung Transplantation, enhancing clinical guidelines and multidisciplinary care in cardiovascular medicine.